188 related articles for article (PubMed ID: 12817887)
1. Absorption rate limit considerations for oral phosphate prodrugs.
Heimbach T; Oh DM; Li LY; Forsberg M; Savolainen J; Leppänen J; Matsunaga Y; Flynn G; Fleisher D
Pharm Res; 2003 Jun; 20(6):848-56. PubMed ID: 12817887
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs.
Heimbach T; Oh DM; Li LY; Rodríguez-Hornedo N; Garcia G; Fleisher D
Int J Pharm; 2003 Aug; 261(1-2):81-92. PubMed ID: 12878397
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds.
Chan OH; Schmid HL; Stilgenbauer LA; Howson W; Horwell DC; Stewart BH
Pharm Res; 1998 Jul; 15(7):1012-8. PubMed ID: 9688053
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
Leppänen J; Savolainen J; Nevalainen T; Forsberg M; Huuskonen J; Taipale H; Gynther J; Männistö PT; Järvinen T
J Pharm Pharmacol; 2001 Nov; 53(11):1489-98. PubMed ID: 11732751
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the oral bioavailability of phenytoin by N-acetylation and absorptive characteristics.
Ogiso T; Tanino T; Kawaratani D; Iwaki M; Tanabe G; Muraoka O
Biol Pharm Bull; 1998 Oct; 21(10):1084-9. PubMed ID: 9821815
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs.
Yuan H; Li N; Lai Y
Drug Metab Dispos; 2009 Jul; 37(7):1443-7. PubMed ID: 19372225
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
[TBL] [Abstract][Full Text] [Related]
8. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
Brouwers J; Tack J; Augustijns P
Int J Pharm; 2007 May; 336(2):302-9. PubMed ID: 17207947
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
Forsberg M; Savolainen J; Järvinen T; Leppänen J; Gynther J; Männistö PT
Pharmacol Toxicol; 2002 Jun; 90(6):327-32. PubMed ID: 12403054
[TBL] [Abstract][Full Text] [Related]
10. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
Alqahtani S; Kaddoumi A
Biopharm Drug Dispos; 2015 Dec; 36(9):587-602. PubMed ID: 26295926
[TBL] [Abstract][Full Text] [Related]
11. Transport of levovirin prodrugs in the human intestinal Caco-2 cell line.
Li F; Hong L; Mau CI; Chan R; Hendricks T; Dvorak C; Yee C; Harris J; Alfredson T
J Pharm Sci; 2006 Jun; 95(6):1318-25. PubMed ID: 16634069
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
13. Fosphenytoin (Cerebyx).
Browne TR
Clin Neuropharmacol; 1997 Feb; 20(1):1-12. PubMed ID: 9037568
[TBL] [Abstract][Full Text] [Related]
14. Development and application of an ex vivo fosphenytoin nasal bioconversion/permeability evaluation method.
Antunes Viegas D; Rodrigues M; Francisco J; Falcão A; Alves G; Santos AO
Eur J Pharm Sci; 2016 Jun; 89():61-72. PubMed ID: 27106504
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.
Savolainen J; Leppanen J; Forsberg M; Taipale H; Nevalainen T; Huuskonen J; Gynther J; Mannisto PT; Jarvinen T
Life Sci; 2000; 67(2):205-16. PubMed ID: 10901288
[TBL] [Abstract][Full Text] [Related]
16. Oxidative activation of acylguanidine prodrugs: intestinal presystemic activation in rats limits absorption and can be inhibited by co-administration of ketoconazole.
Humphreys WG; Obermeier MT; Chong S; Kimball SD; Das J; Chen P; Moquin R; Han WC; Gedamke R; White RE; Morrison RA
Xenobiotica; 2003 Jan; 33(1):93-106. PubMed ID: 12519697
[TBL] [Abstract][Full Text] [Related]
17. Prodrug approach for alphaIIbbeta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): comparison of in vitro and in vivo data.
Kamm W; Raddatz P; Gante J; Kissel T
Pharm Res; 1999 Oct; 16(10):1527-33. PubMed ID: 10554093
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a water-soluble prodrug of entacapone.
Leppänen J; Huuskonen J; Savolainen J; Nevalainen T; Taipale H; Vepsäläinen J; Gynther J; Järvinen T
Bioorg Med Chem Lett; 2000 Sep; 10(17):1967-9. PubMed ID: 10987428
[TBL] [Abstract][Full Text] [Related]
19. Ethylene glycol-linked amino acid diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability and pharmacokinetics.
Cao F; Jia J; Yin Z; Gao Y; Sha L; Lai Y; Ping Q; Zhang Y
Mol Pharm; 2012 Aug; 9(8):2127-35. PubMed ID: 22352697
[TBL] [Abstract][Full Text] [Related]
20. Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs.
Stella VJ; Martodihardjo S; Rao VM
J Pharm Sci; 1999 Aug; 88(8):775-9. PubMed ID: 10430541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
